July 2006, Vol. 7, No. 5, Pages 759-771
, DOI 10.2217/14622416.7.5.759
Review
The application of CD antigen proteomics to pharmacogenomics
Adrian Woolfson
1†, Peter Ellmark
2,3, Jeremy S Chrisp
4, Mike A Scott
5 & Richard I Christopherson
21University of Cambridge School of Clinical Medicine, Addenbrooke’s Hospital, Hills Road, Box 11, Cambridge CB2 2SP, UK.
aw135@cam.ac.uk 2Univerity of Sydney School of Molecular & Microbial Biosciences NSW 2006 Australia
3Lund University Department of Immunotechnology, BMC D13 SE-221 84 Lund, Sweden
4Medsaic Pty Ltd, Suite 145, National Innovation Centre, Australian Technology Park, Garden Street, Eveleigh, NSW 1430, Australia
5University of Cambridge, Department of Haematology, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 2QQ, UK
†
Author for correspondence The advent of multiplexing technologies has raised the possibility that disease states can be defined using discrete genomic and proteomic patterns or signatures. However, this emerging area has been limited by the ‘content problem’, arising from the uncertainty of which molecules to focus on. The human cluster of differentiation (CD) antigens are expressed on cells of the human immune system (leukocytes) and on other cell types. These heterogeneous molecules perform a host of roles essential to immune function and to the physiology of other lineages. The 339 defined CD antigens and their, as yet, undefined counterparts constitute key components of the expressed human cell surface proteome. We propose that CD antigen expression patterns will form the basis of a rational, discrete and generalized diagnostic and prognostic system. Furthermore, disease-specific CD antigen proteomic signatures are likely to be more robust than corresponding genomic signatures and will also help to identify molecular targets for therapeutic intervention.